
Stryker (SYK) Stock Forecast & Price Target
Stryker (SYK) Analyst Ratings
Bulls say
Stryker demonstrated significant financial growth across several key segments, with knee procedures recording a notable increase of 7.6% in the U.S. and 8.8% internationally, alongside strong performance in robotic-assisted technologies. The company achieved an impressive operating margin of 30.2%, reflecting a year-over-year improvement driven by robust sales activity, particularly in new Mako installations, and organic sales growth reaching 11.0% in the most recent quarter. Additionally, Stryker's peripheral vascular and neurotechnology divisions experienced substantial growth, contributing to total sales of $4.562 billion, which surpassed consensus expectations and underscored the company's broad-based strength across its diverse product offerings.
Bears say
Stryker faces several challenges that contribute to a negative outlook, including potential disruptions from recent acquisitions and a deceleration in Mako system utilization amid increased competition. Organic revenue growth is projected to slow to 8% or less due to unsuccessful new product launches and revenue dis-synergies, which may lead to below-consensus earnings performance. Additionally, Stryker's gross margin declined to 65.2%, falling short of consensus expectations, while ongoing risks such as slower orthopedic market growth and a decline in hospital capital spending could further impact the company's financial standing.
This aggregate rating is based on analysts' research of Stryker and is not a guaranteed prediction by Public.com or investment advice.
Stryker (SYK) Analyst Forecast & Price Prediction
Start investing in Stryker (SYK)
Order type
Buy in
Order amount
Est. shares
0 shares